Modelling the potential financial impacts of expanding access to immune checkpoint inhibitors as monotherapy for treating advanced non-small cell lung cancerResearch in context

Summary: Background: Access to immune checkpoint inhibitors remains limited due to cost-effectiveness and affordability concerns. This study evaluates the financial impacts of expanding global access to PD1/PD-L1 inhibitors as first-line monotherapy for patients aged 40–74 years with advanced unres...

全面介紹

書目詳細資料

Principais autores:	Kiu Tay-Teo, Dario Trapani, Manju Sengar, Zeba Aziz, Filip Meheus, André Ilbawi, Elisabeth G.E. de Vries, Lorenzo Moja
格式:	Artigo
語言:	Inglês
出版:	Elsevier 2025-06-01
叢編:	EClinicalMedicine
主題:	Non-small cell lung cancer Immune checkpoint inhibitor Access to medicines Economics Finances
在線閱讀:	http://www.sciencedirect.com/science/article/pii/S2589537025001932
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!